Clinically significant cancer was detected in 29.2 versus 29.6 percent of men with biparametric and multiparametric MRI.

Given the potential for volatility in future cancer research and global health funding from the USA due to federal funding cuts, there might be increased strategic value in other countries ...

Most adverse events in the combination group were attributed to lenvatinib and could be managed by dose reduction or symptomatic treatment.

Researchers examined potential differences in the risk factor profiles of nevus-associated vs de novo melanoma.

Researchers conducted a retrospective cohort study to assess the features associated with disease persistence among pediatric patients with thyroid cancer.

A pilot study sought to measure the impact of Program CONNECT on the confidence, knowledge, and skills of health professional trainees to navigate patients through lung cancer screening.

Researchers investigated the association between lifestyle changes after screening for colonoscopy and the development of ...

HealthDay News — For patients treated with nicotinamide, the risk for skin cancer is reduced, especially when initiated after ...

Researchers analyzed data from the FAERS to determine the prevalence of interstitial lung disease among patients with cancer receiving antibody-drug conjugates ...

Rinatabart sesutecan is an investigational folate receptor alpha-directed, topoisomerase I inhibitor antibody-drug conjugate.

Study results suggest that “clinicians may be unaware of important clinical trial limitations identified by the FDA when making prescribing decisions,” researchers wrote.

Researchers sought to determine whether adding tafasitamab to lenalidomide plus rituximab would maintain quality of life outcomes for patients with FL.